Hofmann et al., subsequently assessed frequency and diversity of LAA-specific cytotoxic T cells in a cohort of 11 patients who had received allogeneic HSCT for different hematologic malignancies, including two NPM1-mutated AML cases in molecular relapse, before and after having received unmanipulated DLI [59]. This evidence concerns the gene NPM1 and acute myeloid leukemia.